Increased commercial momentum and great interest in CADScor® System on the US market 2022 has started off positiv with important steps on the US market, recruitment of key staff and continued validation that our business model works. We report doubled […]
Tag: Acarix
Acarix receives strategic order for the CADScor®System in US
Acarix today announces first order of the CADScor®System in the US from Apex Heart and Vascular Center led by renowned cardiologist Dr. Anuj Shah. The CADScor®System will used at the New Jersey-based APEX clinics for rapid AI-based diagnostics of patients […]
Correction of press release: Acarix AB (publ) publishes Year-End Report 2021
Press release Malmö, Sweden, February 17, 2022 Correction of press release: Acarix AB (publ) publishes Year-End Report 2021 The press release published today at 08.00 CET did not include the quarterly report. The quarterly report is included in the press release below, which otherwise correspond to […]
Acarix submits breakthrough designation request with FDA for heart failure diagnosis
Malmö, Sweden, February 9, 2022 Acarix submits breakthrough designation request with FDA for heart failure diagnosis Acarix expands its portfolio and submits a breakthrough designation request for its innovative technology for heart failure diagnosis with the Food and Drug Administration (FDA) in USA. Heart failure […]
Acarix appoints US based Helen Ljungdahl Round as new CEO
The Board of Acarix AB (publ) has today appointed Helen Ljungdahl Round as new Chief Executive Officer, with immediate effect. Helen is currently President of Acarix USA Inc. and will continue to be based in the US in her capacity […]
Acarix carries out a directed issue of shares to guarantors in conjunction with completed rights issue
Acarix AB (”Acarix” or the “Company”) has, as previously announced, completed the rights issue of shares amounting to approximately SEK 79.3 million (the ”Rights Issue”), which was announced on 5 November 2021 and the outcome of the Rights Issue was […]
Acarix announce final outcome in rights issue
Acarix AB (“Acarix” or the “Company”) has completed the new share issue of a maximum of 105 784 311 shares with preferential rights for the Company’s existing shareholders, which was resolved by the extra general meeting on 23 November 2021 […]
Proximo Medical Named Commercialization Partner for Acarix
LONGMONT, Colo., Nov. 18, 2021 /PRNewswire/ — Proximo Medical, LLC, a business acceleration solution that addresses medical device commercialization challenges among startup and established medical device technologies looking to expand adoption in the U.S., today announced a partnership with Acarix, a Swedish medical device company […]
Acarix accelerates US market entry with Proximo Medical as commercialization partner
Press release (MAR) Malmö, Sweden, November 9, 2021 Acarix accelerates US market entry with Proximo Medical as commercialization partner Acarix today announced the signing of a Commercial Access agreement with Proximo Medical, LLC, to rapidly initiate the commercialization of the CADScor system […]
Acarix granted US CPT reimbursement code for CADScor System
Malmö, Sweden, October 27, 2021 Acarix granted US CPT reimbursement code for CADScor System The editorial panel of the American Medical Association (AMA) today approved the Category III CPT® (CPT III) code application for the Acarix CADScor System®. The application […]